AI-ECG for Cardiomyopathy Prediction
Cardiomyopathy in patients with Premature Ventricular Complexes (PVCs)
Development/ValidationActive
Key Facts
Indication
Cardiomyopathy in patients with Premature Ventricular Complexes (PVCs)
Phase
Development/Validation
Status
Active
Company
About HeartSciences
HeartSciences is developing a suite of AI-enhanced electrocardiography (AI-ECG) diagnostic solutions to address the critical gap in early heart disease detection. The company offers both a cloud-based platform (MyoVista Insights) that works with existing ECG devices and a proprietary hardware device (MyoVista wav ECG) that incorporates its AI algorithms. By leveraging AI to uncover subtle cardiac dysfunction from ECG signals, HeartSciences targets the massive global cardiovascular diagnostics market, seeking to enable earlier intervention and improve patient outcomes. The company is building a broad portfolio of AI-ECG algorithms backed by clinical publications.
View full company profile